Ardent Health, Inc.

NYSE:ARDT Stock Report

Market Cap: US$1.2b

Ardent Health Valuation

Is ARDT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ARDT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ARDT ($8.67) is trading above our estimate of future cash flow value ($5.73)

Significantly Below Future Cash Flow Value: ARDT is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARDT?

Key metric: As ARDT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ARDT. This is calculated by dividing ARDT's market cap by their current earnings.
What is ARDT's PE Ratio?
PE Ratio9.1x
EarningsUS$135.81m
Market CapUS$1.22b

Price to Earnings Ratio vs Peers

How does ARDT's PE Ratio compare to its peers?

The above table shows the PE ratio for ARDT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.8x
USPH U.S. Physical Therapy
52.2x30.27%US$1.1b
SEM Select Medical Holdings
14.1x-3.25%US$2.0b
CON Concentra Group Holdings Parent
16.6x12.12%US$2.8b
NHC National HealthCare
20.5xn/aUS$2.5b
ARDT Ardent Health
9.1x11.72%US$1.2b

Price-To-Earnings vs Peers: ARDT is good value based on its Price-To-Earnings Ratio (9.1x) compared to the peer average (25.8x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does ARDT's PE Ratio compare vs other companies in the US Healthcare Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CYH Community Health Systems
0.8x-117.81%US$393.56m
IDXG Interpace Biosciences
2.1xn/aUS$45.97m
NIVF NewGenIvf Group
0.07x44.27%US$1.11m
IMTH AnTix Holdings
0.09xn/aUS$108.15k
ARDT 9.1xIndustry Avg. 21.8xNo. of Companies9PE01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ARDT is good value based on its Price-To-Earnings Ratio (9.1x) compared to the US Healthcare industry average (21.8x).

Price to Earnings Ratio vs Fair Ratio

What is ARDT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARDT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9.1x
Fair PE Ratio19x

Price-To-Earnings vs Fair Ratio: ARDT is good value based on its Price-To-Earnings Ratio (9.1x) compared to the estimated Fair Price-To-Earnings Ratio (19x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ARDT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$8.67
US$12.73
+46.87%
13.18%US$15.00US$8.80n/a12
Mar ’27US$9.39
US$13.07
+39.16%
14.75%US$16.00US$8.80n/a12
Feb ’27US$8.17
US$13.07
+59.93%
14.75%US$16.00US$8.80n/a12
Jan ’27US$8.83
US$13.67
+54.78%
15.62%US$17.00US$10.00n/a12
Dec ’26US$8.79
US$13.96
+58.80%
15.65%US$17.00US$10.00n/a12
Nov ’26US$14.56
US$19.08
+31.02%
15.17%US$23.00US$12.00n/a13
Oct ’26US$13.08
US$19.08
+45.90%
15.79%US$23.00US$12.00n/a12
Sep ’26US$12.69
US$19.27
+51.87%
15.97%US$23.00US$12.00n/a11
Aug ’26US$10.22
US$20.24
+98.01%
13.04%US$24.00US$14.60n/a11
Jul ’26US$13.73
US$20.32
+47.98%
12.16%US$24.00US$15.50n/a11
Jun ’26US$14.48
US$20.32
+40.32%
12.16%US$24.00US$15.50n/a11
May ’26US$12.59
US$19.90
+58.06%
11.99%US$24.00US$16.00n/a10
Apr ’26US$12.97
US$20.60
+58.83%
9.51%US$24.00US$17.00US$8.6710
Mar ’26US$14.66
US$21.60
+47.34%
9.76%US$25.00US$17.00US$9.3910
Feb ’26US$15.00
US$21.80
+45.33%
7.89%US$25.00US$19.00US$8.1710
Jan ’26US$17.08
US$22.60
+32.32%
10.32%US$27.00US$19.00US$8.8310
Dec ’25US$15.98
US$22.50
+40.80%
10.93%US$27.00US$19.00US$8.7910
Nov ’25US$17.70
US$22.60
+27.68%
9.11%US$27.00US$19.00US$14.5610
Oct ’25US$18.91
US$22.40
+18.46%
8.97%US$27.00US$19.00US$13.0810
Sep ’25US$19.83
US$22.40
+12.96%
8.97%US$27.00US$19.00US$12.6910
US$12.73
Fair Value
31.9% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/01 22:02
End of Day Share Price 2026/04/01 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ardent Health, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kevin FischbeckBofA Global Research
Kevin FischbeckBofA Global Research
Jason CassorlaCitigroup Inc